SUNNYVALE, Calif., Sept. 14 /PRNewswire/ -- Molecular Devices, Inc., a long-time leader in bioanalytical systems for microplate analysis, today announced the launch of two new multi-mode detection platforms that expand its portfolio of microplate readers, enabling the company to meet all combinations of customer needs now and into the future.
Both products will be showcased at Miptec 2010, Switzerland, September 20-24, as well as several other 2010 shows including Het, Scanlab, Biotechnica, SBS China, Society for Neuroscience, and American Society for Cell Biology. Please check www.MolecularDevices.com for details.
The SpectraMax® Paradigm® Platform is the only user-upgradeable multi-mode reader on the market today and is ideal for drug discovery research, including high-throughput screening. The FilterMax™ F3 and F5 Series Readers deliver unmatched assay performance compared to similarly priced readers and are ideal for a wide range of life science research applications. Both platforms were developed in response to requests from existing customers, and both are commercially available with shipping to begin in early October.
"With these two new platforms, we now have an ideal microplate reader for any combination of application, detection, and budget needs," said Mark Verheyden, President of Molecular Devices. "We've carefully expanded our portfolio to ensure that we will be able to meet our customers' needs across ever-evolving research environments. By adding the SpectraMax Paradigm and FilterMax™ F Series Platforms to our existing lines of readers, we now offer the most comprehensiv
|SOURCE Molecular Devices, Inc.|
Copyright©2010 PR Newswire.
All rights reserved